Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2018, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 2, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Fibromyalgia - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibromyalgia - Overview
Fibromyalgia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibromyalgia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibromyalgia - Companies Involved in Therapeutics Development
Aptinyx Inc
Astellas Pharma Inc
Daiichi Sankyo Co Ltd
Innovative Med Concepts LLC
Intec Pharma Ltd
Jiangsu Hengrui Medicine Co Ltd
KPI Therapeutics Inc
Merck & Co Inc
Pfizer Inc
Prismic Pharmaceuticals Inc
Switch Biotech LLC
Fibromyalgia - Drug Profiles
(cannabidiol + dronabinol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-1069562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-0819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-8062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirogabalin besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirtazapine ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-2925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SWT-06101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U-2902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VNP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibromyalgia - Dormant Projects
Fibromyalgia - Discontinued Products
Fibromyalgia - Product Development Milestones
Featured News & Press Releases
Aug 01, 2017: Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions
Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
Mar 22, 2017: Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies
Mar 07, 2017: Journal of Pain Research Publishes Results of PRID-201, a successful Phase 2 Trial using IMC-1 for the Treatment of Fibromyalgia
Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study
Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin
Nov 19, 2012: Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia
Jul 23, 2012: Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica's Discontinuation Effects In Patients With Generalized Anxiety Disorder
Feb 02, 2009: UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Fibromyalgia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Fibromyalgia - Pipeline by Aptinyx Inc, H1 2018
Fibromyalgia - Pipeline by Astellas Pharma Inc, H1 2018
Fibromyalgia - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Fibromyalgia - Pipeline by Innovative Med Concepts LLC, H1 2018
Fibromyalgia - Pipeline by Intec Pharma Ltd, H1 2018
Fibromyalgia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Fibromyalgia - Pipeline by KPI Therapeutics Inc, H1 2018
Fibromyalgia - Pipeline by Merck & Co Inc, H1 2018
Fibromyalgia - Pipeline by Pfizer Inc, H1 2018
Fibromyalgia - Pipeline by Prismic Pharmaceuticals Inc, H1 2018
Fibromyalgia - Pipeline by Switch Biotech LLC, H1 2018
Fibromyalgia - Dormant Projects, H1 2018
Fibromyalgia - Dormant Projects, H1 2018 (Contd..1), H1 2018
Fibromyalgia - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Fibromyalgia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Pain Management Drugs Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 93
Pain is complex, so there are many treatment options -- medications, therapies, and mind-body techniques.
This report is mainly about The drugs for pain management.
The global Pain Management Drugs market was valued at US$ 35360 million in 2023 and is anticipated to reach US$ 44550 million by 2030, witnessing a CAGR of 3.3% during The forecast period 2024-2030.
The leading manufacturers in The industry are GSK, Pfizer and Grunenthal, which accounted for 14.42%, 13......
Global Pain Management Drugs Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Pain Management Drugs market size was valued at US$ 34590 million in 2023. With growing demand in downstream market, the Pain Management Drugs is forecast to a readjusted size of US$ 43780 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Pain Management Drugs market. Pain Management Drugs are expected to show stable growth in the future market. However......
Global Opioids Drug Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 115
According to our LPI (LP Information) latest study, the global Opioids Drug market size was valued at US$ 9831.4 million in 2023. With growing demand in downstream market, the Opioids Drug is forecast to a readjusted size of US$ 8616.1 million by 2030 with a CAGR of -1.9% during review period.
The research report highlights the growth potential of the global Opioids Drug market. Opioids Drug are expected to show stable growth in the future market. However, product differentiation, reduci......
Global Methadone Hydrochloride Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 90
According to our LPI (LP Information) latest study, the global Methadone Hydrochloride market size was valued at US$ 63 million in 2023. With growing demand in downstream market, the Methadone Hydrochloride is forecast to a readjusted size of US$ 88 million by 2030 with a CAGR of 5.0% during review period.
The research report highlights the growth potential of the global Methadone Hydrochloride market. Methadone Hydrochloride are expected to show stable growth in the future market. Howev......
Global Opioids Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 02-Jan-2024 Price: US 3380 Onwards Pages: 112
Market Overview of Global Opioids Drugs market:
According to our latest research, the global Opioids Drugs market looks promising in the next 5 years. As of 2022, the global Opioids Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescript......
Global Opioids Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 111
According to our (Global Info Research) latest study, the global Opioids Drug market size was valued at USD 10340 million in 2023 and is forecast to a readjusted size of USD 9156.6 million by 2030 with a CAGR of -1.7% during review period.
Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin®), hydrocodone (Vicodin®), codeine, morphine, and many others. The......
Global Methadone Hydrochloride Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 87
According to our (Global Info Research) latest study, the global Methadone Hydrochloride market size was valued at USD 66 million in 2023 and is forecast to a readjusted size of USD 90 million by 2030 with a CAGR of 4.6% during review period.
Methadone Hydrochloride is a white, crystalline material that is water-soluble. It is an opioid used to treat pain or as maintenance therapy to help with detoxification in people with opioid dependence.
Market Competition is not intense, as t......
Global Pain Management Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 131
According to our (Global Info Research) latest study, the global Pain Management Drugs market size was valued at USD 36380 million in 2023 and is forecast to a readjusted size of USD 45230 million by 2030 with a CAGR of 3.2% during review period.
Pain is complex, so there are many treatment options -- medications, therapies, and mind-body techniques.
This report is mainly about the drugs for pain management.
The leading manufacturers in the industry are GSK, Pfizer and Grune......
Global Fibromyalgia Drugs Market Research Report 2023, Forecast to 2028
Published: 28-Dec-2023 Price: US 2680 Onwards Pages: 167
The FDA has approved three drugs to treat fibromyalgia: the antidepressants duloxetine (Cymbalta) and milnacipran (Savella), plus the anti-seizure medicine pregabalin (Lyrica).
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging oppo......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
